TuisOGN • NYSE
add
Organon & Co
Vorige sluiting
$16,00
Dagwisseling
$15,75 - $16,10
Jaarwisseling
$13,87 - $23,10
Markkapitalisasie
4,08 mjd USD
Gemiddelde volume
3,97 m
P/V-verhouding
3,14
Dividend-opbrengs
7,07%
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,58 mjd | 4,15% |
Bedryfskoste | 533,00 m | -21,04% |
Netto inkomste | 359,00 m | 518,97% |
Netto winsgrens | 22,69 | 493,98% |
Wins per aandeel | 0,87 | 0,00% |
EBITDA | 459,00 m | 56,66% |
Effektiewe belastingkoers | -73,43% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 763,00 m | 84,30% |
Totale bates | 12,75 mjd | 15,80% |
Totale aanspreeklikheid | 12,26 mjd | 5,67% |
Totale ekwiteit | 493,00 m | — |
Uitstaande aandele | 257,54 m | — |
Prys om te bespreek | 8,38 | — |
Opbrengs op bates | 7,83% | — |
Opbrengs op kapitaal | 10,81% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 359,00 m | 518,97% |
Kontant van bedrywe | 141,00 m | -45,98% |
Kontant van beleggings | -75,00 m | -36,36% |
Kontant van finansiering | -78,00 m | 0,00% |
Netto kontantverandering | 59,00 m | -32,95% |
Beskikbare kontantvloei | 29,00 m | -85,07% |
Meer oor
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Wikipedia
Gestig
2020
Webwerf
Werknemers
10 000
